CN113755421A - 一种用于covid-19的口服性疫苗及抗体加强剂 - Google Patents
一种用于covid-19的口服性疫苗及抗体加强剂 Download PDFInfo
- Publication number
- CN113755421A CN113755421A CN202111143384.9A CN202111143384A CN113755421A CN 113755421 A CN113755421 A CN 113755421A CN 202111143384 A CN202111143384 A CN 202111143384A CN 113755421 A CN113755421 A CN 113755421A
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- bacillus subtilis
- protein
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 23
- 229940126578 oral vaccine Drugs 0.000 title abstract description 6
- 239000003623 enhancer Substances 0.000 title abstract description 5
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 99
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 96
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 95
- 229940096437 Protein S Drugs 0.000 claims abstract description 40
- 101710198474 Spike protein Proteins 0.000 claims abstract description 33
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims abstract description 28
- 102000005962 receptors Human genes 0.000 claims abstract description 27
- 108020003175 receptors Proteins 0.000 claims abstract description 27
- 230000009385 viral infection Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 37
- 229960005486 vaccine Drugs 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims 1
- 102100031673 Corneodesmosin Human genes 0.000 description 24
- 101710139375 Corneodesmosin Proteins 0.000 description 19
- 101710141454 Nucleoprotein Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108010031318 Vitronectin Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000007837 multiplex assay Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种用于COVID‑19的口服性疫苗及抗体加强剂。具体地,本发明提供一种枯草芽孢杆菌,所述的枯草芽孢杆菌表达SARS‑CoV‑2的核衣壳蛋白和/或SARS‑CoV‑2的刺突蛋白的受体结合区域。本发明所述的基因工程化的枯草芽孢杆菌的口服性疫苗及抗体加强剂能够用于预防和/或治疗SARS‑CoV‑2病毒感染或COVID‑19。
Description
技术领域
本发明涉及药物领域,具体地,本发明涉及一种用于COVID-19的口服性疫苗及抗体加强剂。
背景技术
由SARS-CoV-2病毒引起的COVID-19(Corona Virus Disease 2019,新型冠状病毒肺炎)大流行对人类健康造成重大威胁。针对SARS-CoV-2的疫苗是控制疾病传播的有效手段,目前虽然有多种疫苗处于开发阶段,但疫苗的疗效、安全性和患者顺从性方面还存在许多问题,例如疫苗施用后血清抗体水平低、注射给药疫苗对药物的安全性带来问题,且患者对注射给药的顺从性低等等。
因此,本领域需要开发一种有效、安全性高和患者顺从性好的用于SARS-CoV-2病毒的疫苗。
发明内容
本发明的目的在于提供一种有效、安全性高和患者顺从性好的用于SARS-CoV-2病毒的疫苗。
本发明的第一方面提供了一种枯草芽孢杆菌,所述的枯草芽孢杆菌表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域。
优选地,所述的枯草芽孢杆菌为基因工程化的枯草芽孢杆菌。
优选地,枯草芽孢杆菌的菌株包括枯草芽孢杆菌WB800N菌株。
优选地,所述的SARS-CoV-2的核衣壳蛋白的核苷酸序列如SEQ ID NO:1所示。
优选地,所述的SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如SEQ IDNO:2所示。
优选地,所述的枯草芽孢杆菌通过以下方法制备:
将表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域掺入或导入到所述的枯草芽孢杆菌中,表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域,得到枯草芽孢杆菌。
本发明第二方面,提供一种转化子,所述的转化子包括含有表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域的基因的枯草芽孢杆菌。
优选地,所述的基因包括DNA和/或RNA。
优选地,所述的基因掺入或导入到所述的枯草芽孢杆菌中。
优选地,枯草芽孢杆菌的菌株包括枯草芽孢杆菌WB800N菌株。
优选地,所述的表达SARS-CoV-2的核衣壳蛋白的基因的核苷酸序列如SEQ ID NO:1所示。
优选地,所述的表达SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如SEQID NO:2所示。
优选地,所述的基因负载在质粒上。
优选地,所述的质粒包括穿梭载体pHT01。
优选地,所述的表达SARS-CoV-2的核衣壳蛋白的基因的核苷酸序列如SEQ ID NO:3所示。
优选地,所述的表达SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如SEQID NO:4所示。
优选地,所述的转化子通过以下方法制备:
将表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域掺入或导入到所述的枯草芽孢杆菌中,得到转化子。
本发明第三方面,提供一种组合物,所述的组合物包括如本发明第一方面所述的枯草芽孢杆菌和/或如本发明第二方面所述的转化子。
优选地,所述的组合物为药物组合物或疫苗组合物。
优选地,所述的组合物还包括药学上、疫苗上可接受的载体。
优选地,所述的组合物的剂型为注射用制剂、外用制剂或口服制剂。
优选地,所述的组合物的剂型为口服制剂。
优选地,所述的组合物的剂型为肠道口服制剂。
优选地,所述的组合物的剂型为小肠口服制剂。
优选地,所述的组合物的剂型为固体制剂、液体制剂或半固体制剂。
优选地,所述的组合物的剂型为片剂、胶囊剂、散剂、注射剂、粉针剂、乳剂、输液剂、口服液、气雾剂、膏剂、凝胶剂、微球、霜剂。
本发明第四方面,提供一种如本发明第一方面所述的枯草芽孢杆菌和/或如本发明第二方面所述的转化子的用途,用于制备组合物,所述的组合物用于预防和/或治疗SARS-CoV-2病毒感染或COVID-19;和/或用作SARS-CoV-2抗体的加强剂。
优选地,所述的SARS-CoV-2抗体包括接种Sinovac-Corona疫苗产生的抗体。
优选地,所述的组合物的剂型为注射用制剂、外用制剂或口服制剂。
优选地,所述的组合物为药物组合物或疫苗组合物。
优选地,所述的组合物还包括药学上、疫苗上可接受的载体。
优选地,所述的组合物的剂型为口服制剂。
优选地,所述的组合物的剂型为肠道口服制剂。
优选地,所述的组合物的剂型为小肠口服制剂。
本发明第五方面,提供一种制备抗SARS-CoV-2的核衣壳蛋白和/或抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体的方法,所述的方法包括步骤:
将如本发明第一方面所述的枯草芽孢杆菌和/或如本发明第二方面所述的转化子口服给药对象,从血液中分离得到抗SARS-CoV-2的核衣壳蛋白的抗体和/或抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体。
优选地,所述的方法为非诊断性和非治疗性方法。
优选地,所述对象为人和非人哺乳动物。
优选地,所述的非人哺乳动物为鼠、狗、猫、牛、羊、马、猪。
本发明第六方面,提供一种预防和/或治疗SARS-CoV-2病毒感染或COVID-19的方法,所述的方法包括步骤:口服给予所述的对象如如本发明第一方面所述的枯草芽孢杆菌和/或如本发明第二方面所述的转化子,从而预防和/或治疗SARS-CoV-2病毒感染或COVID-19。
优选地,所述对象为人和非人哺乳动物。
优选地,所述的非人哺乳动物为鼠、狗、猫、牛、羊、马、猪。
在本发明范围内中,本发明的上述各技术特征和在下文中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。
附图说明
图1为SARS-CoV-2的S蛋白的构建质粒的参考示意图。
图2为表达SARS-CoV-2的N蛋白和S蛋白表达的基因工程化枯草芽孢杆菌的蛋白质印迹。
图3为用Anti-SRBD-AF488染色的野生芽孢杆菌的孢子和表达S蛋白的基因工程化的芽孢杆菌孢子。
图4为基因工程化枯草芽孢杆菌孢子的S蛋白印迹。
图5为野生型枯草芽孢杆菌和含有S蛋白的基因工程化枯草芽孢杆菌孢子的免疫染色。
图6为野生型枯草芽孢杆菌和基因工程化枯草芽孢杆菌孢子的流式细胞术分析。
图7为表达N和S蛋白的基因工程化的枯草芽孢杆菌孢子灌胃小鼠后的血清抗S蛋白的抗体。
具体实施方式
本发明开发了一种枯草芽孢杆菌,所述的枯草芽孢杆菌表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域。本发明所述的基因工程化的枯草芽孢杆菌口服能够用于预防和/或治疗SARS-CoV-2病毒感染或COVID-19。此外,本发明所述的基因工程化的枯草芽孢杆菌还能够用作SARS-CoV-2抗体的加强剂,从而提高SARS-CoV-2的治疗效果。
术语
如本文所用,术语“包括”、“包含”与“含有”可互换使用,不仅包括开放式定义,还包括半封闭式、和封闭式定义。换言之,所述术语包括了“由……构成”、“基本上由……构成”。
如本文所用,术语“刺突蛋白”与“Spike蛋白”可互换使用。
如本文所用,术语“受体结合区域”与“RBD”可互换使用。
如本文所用,术语“枯草芽孢杆菌WB800N”与“Bacillus Subtilis WB800N”可互换使用。
在本发明中,术语“预防”表示预防疾病和/或它的附随症状的发作或者保护对象免于获得疾病的方法。
本发明所述的“治疗”包括延缓和终止疾病的进展,或消除疾病,并不需要100%抑制、消灭和逆转。
枯草芽孢杆菌
本发明提供一种枯草芽孢杆菌,所述的枯草芽孢杆菌表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域。
优选地,枯草芽孢杆菌的菌株包括枯草芽孢杆菌WB800N菌株。
在本发明的一个优选例中,所述的SARS-CoV-2的核衣壳蛋白的核苷酸序列如SEQID NO:1所示:
SEQ ID NO:1:
ATGTCAGACAATGGCCCTCAAAACCAGAGAAACGCTCCCCGTATAACTTTTGGAGGACCGTCGGATTCAACAGGTAGCAATCAGAATGGCGAGAGATCTGGCGCAAGGAGTAAACAGCGGAGACCCCAGGGATTACCCAATAATACAGCCTCATGGTTTACTGCCCTAACTCAGCATGGCAAAGAAGATCTTAAGTTTCCTCGGGGTCAAGGCGTACCCATAAATACAAATTCTTCCCCGGATGATCAAATCGGATACTATCGCAGGGCGACTAGACGCATCAGAGGCGGCGATGGCAAGATGAAGGATCTGAGTCCCAGATGGTATTTTTATTATTTGGGAACAGGACCCGAGGCAGGATTACCGTATGGAGCAAACAAGGATGGGATTATTTGGGTGGCTACGGAAGGAGCATTAAATACTCCGAAGGATCACATTGGTACTCGGAACCCGGCAAACAATGCTGCTATTGTCCTTCAATTACCACAAGGCACGACCTTACCGAAAGGCTTTTACGCGGAAGGTTCCCGCGGCGGCTCTCAGGCAAGCTCACGTTCATCATCCAGATCTCGTAATAGCAGCCGGAACTCAACACCCGGAAGTTCGAGAGGGACAAGCCCTGCGCGAATGGCAGGAAACGGTGGCGACGCCGCGCTCGCCTTGTTGCTTTTGGATCGGTTGAATCAGCTTGAGTCAAAAATGTCTGGAAAGGGGCAACAACAACAAGGTCAAACAGTGACGAAAAAATCAGCTGCGGAAGCGTCAAAAAAACCCCGTCAAAAACGCACGGCTACAAAGGCGTATAACGTAACACAAGCATTTGGAAGAAGGGGGCCGGAACAAACGCAAGGTAATTTTGGAGATCAAGAACTGATTAGGCAGGGCACAGACTATAAACACTGGCCGCAGATCGCACAGTTTGCGCCCAGCGCGTCGGCATTTTTCGGCATGTCGCGTATTGGAATGGAGGTCACACCCAGCGGCACATGGCTTACGTATACCGGCGCGATCAAGCTCGACGATAAAGATCCTAACTTTAAAGATCAGGTAATACTGTTGAACAAGCATATAGACGCTTACAAAACGTTTCCCCCTACAGAACCTAAAAAAGATAAAAAAAAAAAAGCGGATGAGACCCAAGCGTTACCCCAGAGACAGAAGAAACAACAAACAGTGACACTGTTACCAGCCGCAGATCTGGATGATTTTAGCAAACAGTTACAACAGTCTATGTCTTCCGCTGATTCAACACAAGCGTAA(SEQ ID NO:1)。
优选地,所述的SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如SEQ IDNO:2所示:
SEQ ID NO:2:
AATATCACGAATTTGTGCCCATTTGGCGAAGTATTCAACGCAACGAGATTTGCCTCCGTTTATGCGTGGAACCGGAAGAGAATCTCAAATTGTGTCGCGGATTATAGCGTCCTGTATAATTCAGCGTCATTCTCCACCTTTAAGTGCTACGGCGTGTCACCAACGAAATTGAATGATCTGTGTTTCACTAATGTATATGCAGATAGCTTTGTGATCCGCGGCGACGAAGTCAGACAAATTGCGCCAGGCCAAACGGGAAAAATCGCAGATTATAATTATAAACTTCCTGATGACTTCACGGGATGTGTAATTGCATGGAACTCTAATAACCTTGATTCGAAAGTCGGAGGAAATTATAACTATCTGTATAGACTGTTCCGCAAGAGCAATCTCAAGCCTTTCGAACGCGATATCTCGACGGAGATTTATCAAGCCGGCAGCACCCCGTGTAACGGTGTTGAAGGCTTCAATTGCTATTTCCCGCTGCAGAGCTATGGCTTTCAACCGACGAACGGGGTTGGCTACCAGCCCTACCGCGTCGTGGTTCTGTCCTTCGAATTACTCCATGCCCCGGCTACGGTTTAATGAAA(SEQ ID NO:2)。
转化子
转化子(transformant)是掺入或导入外源DNA后获得了新的遗传标志的细菌细胞或其他受体细胞。转化后的受体菌,称转化子transformant。
本发明提供一种转化子,所述的转化子包括含有表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域的基因的枯草芽孢杆菌。
优选地,所述的基因包括DNA和/或RNA。
优选地,所述的基因掺入或导入到所述的枯草芽孢杆菌中。
优选地,枯草芽孢杆菌的菌株包括枯草芽孢杆菌WB800N菌株。
优选地,所述的表达SARS-CoV-2的核衣壳蛋白的基因的核苷酸序列如上文SEQ IDNO:1所示。
优选地,所述的表达SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如上文SEQ ID NO:2所示。
优选地,所述的基因负载在质粒上。
优选地,所述的质粒包括穿梭载体pHT01。
优选地,所述的表达SARS-CoV-2的核衣壳蛋白的基因的核苷酸序列如SEQ ID NO:3所示。
优选地,所述的表达SARS-CoV-2的刺突蛋白的受体结合区域的核苷酸序列如SEQID NO:4所示。
组合物
本发明提供了一种组合物,所述的组合物能够用于预防和/或治疗SARS-CoV-2病毒感染或COVID-19。
代表性地,所述的组合物为药物组合物或疫苗组合物。
本发明所述的组合物还可以包括药学上、疫苗上可接受的载体。
在本发明中,组合物的剂型包括(但不限于)口服制剂、注射剂、外用制剂。
代表性地,组合物的剂型包括(但不限于):片剂、胶囊剂、散剂、注射剂、粉针剂、乳剂、输液剂、口服液、气雾剂、膏剂、凝胶剂、微球、霜剂。
术语“药学上、疫苗上可接受的载体”指的是:一种或多种相容性固体、半固体、液体或凝胶填料,它们适合于人体或动物使用,而且必须有足够的纯度和足够低的毒性。“相容性”是指药物组合物中的各组分和药物的活性成分以及它们之间相互掺和,而不明显降低药效。
应理解,在本发明中,所述的载体没有特别的限制,可选用本领域常用材料,或用常规方法制得,或从市场购买得到。药学可接受的载体部分例子有纤维素及其衍生物(如甲基纤维素、乙基纤维素、羟丙甲基纤维素、羧甲基纤维素钠等)、明胶、滑石粉、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油、等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温)、润湿剂(如十二烷基硫酸钠)、缓冲剂、螯合剂、增稠剂、pH调节剂、透皮促进剂、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、抑菌剂、无热原水等。
代表性的,液体剂型除了活性药物成分外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例如,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂等
药物制剂应与给药方式相匹配。本发明药剂还可与其他协同治疗剂一起使用(包括之前、之中或之后使用)。使用药物组合物时,是将安全有效量的药物施用于所需对象(如人或非人哺乳动物),所述安全有效量通常至少约10微克/千克体重,而且在大多数情况下不超过约8毫克/千克体重,较佳地该剂量是约10微克/千克体重-约1毫克/千克体重。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
用途
本发明还提供一种如本发明所述的枯草芽孢杆菌和/或如本发明所述的转化子的用途,用于制备组合物,所述的组合物用于预防和/或治疗SARS-CoV-2病毒感染或COVID-19;和/或用作SARS-CoV-2抗体的加强剂。
本发明还提供一种制备抗SARS-CoV-2的核衣壳蛋白和/或抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体的方法,所述的方法包括步骤:
将如本发明所述的枯草芽孢杆菌和/或如本发明所述的转化子口服给药对象,从血液中分离得到抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体。
优选地,所述的方法为非诊断性和非治疗性方法。
优选地,所述对象为人和非人哺乳动物。
优选地,所述的非人哺乳动物为鼠、狗、猫、牛、羊、马、猪。
本发明还提供一种预防和/或治疗SARS-CoV-2病毒感染或COVID-19的方法,所述的方法包括步骤:口服给予所述的对象如本发明所述的枯草芽孢杆菌和/或如本发明所述的转化子,从而预防和/或治疗SARS-CoV-2病毒感染或COVID-19。
本发明的主要技术效果包括:
本发明开发了一种基因工程化枯草芽孢杆菌,所述的枯草芽孢杆菌表达SARS-CoV-2的核衣壳蛋白和SARS-CoV-2的刺突蛋白的受体结合区域,本发明所述的基因工程化的枯草芽孢杆菌通过口服能够用于预防治疗SARS-CoV-2病毒感染或COVID-19,口服给药成本低、安全性高、服用方便、患者顺应性高。此外,本发明所述的基因工程化的枯草芽孢杆菌还能够用作SARS-CoV-2抗体的加强剂,从而提高SARS-CoV-2的治疗效果。
下面结合具体实施例,进一步阐述本发明。应理解,以下具体实施例以本技术方案为前提,给出了详细的实施方式和具体操作过程,但本发明的保护范围并不限于本实施例。
实施例
SARS-CoV-2的N蛋白为SARS-CoV-2的核衣壳蛋白。
SARS-CoV-2的S蛋白为SARS-CoV-2的刺突蛋白(Spike)的RBD(受体结合区域)。
表达SARS-CoV-2的N和S蛋白的基因工程化枯草芽孢杆菌简称基因工程化枯草芽孢杆菌。
实施例1
1.1表达SARS-CoV-2的N和S蛋白的基因工程化枯草芽孢杆菌的制备
枯草芽孢杆菌WB800N(Bacillus Subtilis WB800N)菌株用于研究。该细菌用编码SARS-CoV-2病毒S/N蛋白的质粒进行转化。枯草芽孢杆菌的孢子形成是用DifcoSporulationMedium从营养细胞诱导的,并进一步用溶酶体处理以去除营养细胞。
包含来自枯草芽孢杆菌的全长CotC级联、肽连接区域和来自SARS-CoV-2的核衣壳蛋白或刺突蛋白(Spike)的RBD(受体结合区域)的表达构建体是针对枯草芽孢杆菌进行密码子优化的,通过InvitrogenGeneArt基因合成,进一步克隆到大肠杆菌(E.coli)和枯草芽孢杆菌的穿梭载体pHT01中。大肠杆菌菌株DH5α(NEB)用于克隆,表达SARS
SARS-CoV-2的N和S蛋白的构建质粒转化到枯草芽孢杆菌菌株WB800N(MoBiTec)中进行N和S蛋白表达。质粒的DNA序列通过Sanger测序确认。
转化到枯草芽孢杆菌菌株WB800N的pHT01-SARS-CoV-2的核衣壳蛋白构建质粒和pHT01-SARS-CoV-2的Spike蛋白的RBD的构建质粒的测序结果如下所示:
pHT01-核衣壳蛋白的核苷酸序列如下SEQ ID NO:3所示:
SEQ ID NO:3:
其中:CotC:无加黑下划线
肽连接区域:加黑斜体
SARS-CoV-2的核衣壳蛋白核苷酸:加黑有下划线
pHT01-Spike蛋白的RBD的核苷酸序列如下SEQ ID NO:4所示:
SEQ ID NO:4:
其中:CotC:无加黑下划线
肽连接区域:加黑斜体
SARS-CoV-2的刺突蛋白的RBD核苷酸序列:加黑有下划线。
SARS-CoV-2的S蛋白的构建质粒的参考示意图如图1所示。
1.2从基因工程化枯草芽孢杆菌中诱导SARS-CoV-2的N和S蛋白
枯草芽孢杆菌转化子将在37℃、200rpm下生长,直到OD600值在补充有氯霉素(5μg/mL)的2xLB中达到1.0。培养物用终浓度为1mM IPTG进行诱导,并在37℃、200rpm下再诱导12h。收集培养物并以4,200rpm离心15min。细胞沉淀将用1x磷酸盐缓冲盐水(PBS,pH7.4)洗涤并重悬于1/2体积的DifcoSporulationMedium(DSM)(8g营养肉汤、0.1%KCl、1mM MgSO4和10μM MnCl2溶于1L蒸馏水中,添加0.5mM CaCl2和1μM FeSO4)。细胞在37℃、200rpm下生长24小时。细胞在37℃下通过溶菌酶(0.1mg/mL)裂解1h,10,000rpm离心15分钟,然后用1xPBS洗涤三次。来自转化的枯草芽孢杆菌孢子用PBS洗涤,用裂解缓冲液(PBS+1%Triton和完全蛋白酶抑制剂)裂解,然后在100℃下变性10min,然后在14,800g下离心15min。进行BCA测定以确定蛋白质浓度。100ng刺突蛋白(spike protein)标准品的RBD和10μg孢子裂解物将在SDS-PAGE中进行分析,然后用针对刺突蛋白的RBD和核衣壳蛋白单克隆抗体进行蛋白印迹考察。
1.3.人单核细胞与肠道HT-29细胞共培养
为了模拟肠道粘膜区域,将采用人单核细胞和肠道HT-29细胞的体外共培养系统。人单核细胞从健康志愿者的新鲜人血沉棕黄层中制备,用于纯化原代人类巨噬细胞。外周血单核细胞(PBMC)将通过Ficoll密度(1.082g/ml)以1800rpm离心25min进行分离。红细胞裂解后,CD14特异性MACS珠(MiltenyiBiotec)将用于富集CD14+单核细胞。为了诱导巨噬细胞分化,CD14+单核细胞将在含有L-谷氨酰胺、10%FCS、1%青霉素-链霉素、1%丙酮酸钠和1%Glutamax(GIBCO)和GM-CSF(25ng/mL)的RPMI1640培养基中培养6-7天和,细胞培养密度为1.5x105/cm2。
将人小肠上皮HT-29细胞在24孔培养板中培养至融合,然后在37℃下用PBS冲洗以防止细胞脱离。然后将单核细胞悬液(5x105/ml)添加到培养板中的HT-29细胞上。上皮细胞-单核细胞共培养物在有或没有野生枯草芽孢杆菌/基因工程化枯草芽孢杆菌中孵育。通过Bio-plex200System(Bio-Rad)的Bio-plex人细胞因子/趋化因子多重分析对培养上清液或小鼠血清中促炎因子(IL-1、IL-6、IL-8、IL-12、干扰素-γ(IFNγ)和TNF-α)的浓度进行定量分析。
1.4.体外细胞分离和DCs的产生
单核细胞将在24孔板中以2×106/ml密度铺在24孔板中,并在37℃和5%CO2条件下粘附45分钟。通过用温和的培养基流冲洗孔2到3次,可以去除未贴壁的细胞。然后在存在两种细胞因子的条件下培养单核细胞:粒细胞巨噬细胞集落刺激因子(50ng/ml)和IL-4(40ng/ml),在37℃和5%CO2条件下培养。在第3天,50%的培养基将替换为新鲜培养基和细胞因子。然后在第6天收集DCs并洗涤。细胞成熟通过野生枯草芽孢杆菌/基因工程化枯草芽孢杆菌诱导48小时。脂多糖(LPS)(0.1g/ml)将用作阳性对照。收获细胞后收集DCs培养物的上清液,并储存在-80℃检测细胞因子。
通过Bio-plex200System(Bio-Rad)的Bio-plex人细胞因子/趋化因子多重分析测定(IL-1、IL-12、IL-10、IFN-γ和TNF-α)的浓度。
1.5.DCs的流式细胞分析
第8天,收集DCs(树突状细胞),洗涤并用荧光色素偶联抗体标记。标记后,清洗细胞悬浮液并重新悬浮以进行流式细胞术分析。FITC、PE和PE-cyanin5.1(PC5)-偶联同型对照和CD11c-APC、CD14-FITC、CD40-PerCP、CD80-FITC、CD83-PE、CD86-PE和HLA-DR-APC抗体。DCs通过标准前向散射和侧向散射曲线测定大细胞,将不同CD标记物的平均荧光强度与RPMI处理的阴性对照的平均荧光强度归一化为相对荧光强度。
1.6.免疫方案
1.6.1首先使用上述体外实验研究和比较野生枯草芽孢杆菌/基因工程化枯草芽孢杆菌的不同组合的免疫调节活性。后续动物研究中使用的是野生枯草芽孢杆菌/基因工程化枯草芽孢杆菌基于体外实验的结果。
使用BALB/小鼠,8周大的小鼠将通过灌胃(p.o.)途径接种野生枯草芽孢杆菌或基因工程化枯草芽孢杆菌的孢子。
第1组:野生未免疫组
第2组:1.0×1010个孢子的基因工程化枯草芽孢杆菌
通过不锈钢圆头饲插管灌胃给予小鼠含有1×1010个孢子的悬浮液(0.5毫升等分试样)。在施用孢子前30min,小鼠灌胃给予0.5ml 0.1M碳酸氢钠溶液。将在免疫方案前三天和第给药后收集血液,测试每个小鼠组的个体血液样品的抗体反应。
1.6.2抗体的血清学
小鼠在全身麻醉下放血,用于ELISA分析,并将血清冷冻以备将来检测。靶向抗原是SARS-CoV-2N和S蛋白。为了确定小鼠血清中抗体的滴度,ELISA平板上涂有抗原,通常为0.1ng/孔。将在含有1%HSA的PBS中连续稀释的血清上清液加入包被板的孔中,并在室温下孵育1h。山羊抗小鼠IgM或IgG与碱性磷酸酶偶联(SouthernBiotechnology,Birmingham,AL,USA)作为二抗。抗体效价定义为最高血清稀释度,其吸光度比正常血清样品的吸光度高0.1或更高。如果反应性滴度从无法检测到的预处理增加到疫苗接种后的至少1:40,或者如果可检测到预处理的8倍,则反应效价通过ELISA测定为阳性的。
1.6.3脾细胞的分离和活化
最后一次免疫后,将处死小鼠,无菌收集脾脏用于脾细胞分离。脾脏将灌注RPMI-1640(添加有10%热灭活胎牛血清、25mM HEPES、2mM L-谷氨酰胺、1mM丙酮酸钠、100IU/ml青霉素和100mg/ml链霉素)和配备26G针头的5ml注射器将用于获得脾细胞的单细胞悬液。脾细胞悬液将在300×g离心5分钟。RBCs使用3ml 0.84%的无菌NH4Cl裂解2分钟。细胞用RPMI-1640洗涤以去除裂解的红细胞和NH4Cl。脾细胞(2×105/ml)将在不存在或存在纯化的重组SARS-CoV-2S和N蛋白的情况下培养48小时。然后将收集含有释放的细胞因子的上清液样品并储存在-80℃。SARS-CoV-2S和N蛋白刺激的细胞分泌的IL-1、IL-6、IL-10、IL-17、IFN-γ和TNF-α的水平将通过Bio-plex200System(Bio-Rad)的Bio-plexhuman进行细胞因子/趋化因子多重分析。
1.7临床试验
志愿者被随机分成未接种疫苗组和接种疫苗组。
对于未接种其它疫苗组的志愿者,志愿者分别在第0天、14天和28天口服1粒含有1x1010CFU基因工程化枯草芽孢杆菌孢子的胶囊,分别在第0天、27天和42天进行血液检测。
对于接种其它疫苗组的志愿者,在接种Sinovac-Corona疫苗4个月后,进行血液检测(计为第0天),然后口服1粒含有1x1010CFU基因工程化枯草芽孢杆菌孢子的胶囊后第14天进行血液检测。
对血液样本进行MAGLUMI SARS-CoV-2中和抗体测试,以定量测定志愿者中抗SARS-CoV-2的中和抗体滴度,测定的检测限为0.003μg/mL。
1.8.统计分析
将使用GraphPadPRISM软件5.0版(GraphPadSoftware,SanDiego,CA,USA)进行统计分析和显着性分析,如通过配对样本的学生t检验或单向方差分析(ANOVA)进行测量。在所有比较中,p<0.05将被视为具有统计学意义。
2.实验结果
2.1从基因工程化的枯草芽孢杆菌中诱导SARS-CoV-2的N蛋白和S蛋白
通过枯草芽孢杆菌裂解物的蛋白质印迹和用抗S蛋白的RBD-AF488染色孢子,证实工程化枯草芽孢杆菌的SARS-CoV-2的N和S蛋白表达,如图2和图3所示。
2.2孢子的表征
通过蛋白质印迹和免疫染色也证实了的孢子特征,如图4和图5所示。染色后的孢子还通过流式细胞仪进一步确认其特征,流式细胞仪分析结果如图6所示。
2.3动物实验
小鼠在第0天开始进行3个疗程给予表达N蛋白和S蛋白的枯草芽孢杆菌孢子的灌胃(First log),第98天后另外连续3天、每天一次的灌胃(Second log)则给予表达S蛋白的枯草芽孢杆菌孢子,小鼠血清中的抗S蛋白的抗体IgM和IgG的含量如图7所示。
可以看出,口服给予表达N蛋白和S蛋白的枯草芽孢杆菌孢子后,血清中能够高含量的产生抗体SARS-CoV-2的S蛋白抗体IgM和IgG,表明表达N蛋白和S蛋白的枯草芽孢杆菌能够口服用作SARS-CoV-2感染的疫苗。
2.4人细胞因子/趋化因子多重分析测定结果
人细胞因子/趋化因子多重分析测定IL-1、IL-12、IL-10、IFN-γ和TNF-α的浓度在人单核细胞与肠道HT-29上皮细胞共培养物和DCs通过野生枯草芽孢杆菌/基因工程化枯草芽孢杆菌诱导下,以及小鼠免疫后分离的脾细胞在存在纯化的重组SARS-CoV-2S和N蛋白活化下,均有显著的上升。
2.5临床试验结果
对于未接种其它疫苗组的志愿者,在口服基因工程化枯草芽孢杆菌孢子的胶囊后的第0天、27天和42天,血液中的抗体SARS-CoV-2的含量如下表1所示:
表1未接种其它疫苗组的志愿者口服基因工程化枯草芽孢杆菌孢子的胶囊后的第0天、27天和42天血液中的抗体SARS-CoV-2中和抗体的含量
志愿者 | 第0天 | 第27天 | 第42天 |
男性(65岁) | <0.003μg/ml | 0.016μg/ml | 0.037μg/ml |
女性(58岁) | <0.003μg/ml | 0.003μg/ml | 0.034μg/ml |
女性(48岁) | <0.003μg/ml | <0.003μg/ml | 0.022μg/ml |
男性(54岁) | <0.003μg/ml | 0.003μg/ml | 0.050μg/ml |
男性(71岁) | <0.003μg/ml | <0.003μg/ml | 0.042μg/ml |
对于接种其它疫苗组的志愿者,在接种Sinovac-Corona疫苗4个月后(计为第0天)和口服基因工程化枯草芽孢杆菌孢子的胶囊后第14天血液中的抗体SARS-CoV-2中和抗体的含量如下表2所示:
表2接种其它疫苗组的志愿者在接种Sinovac-Corona疫苗4个月后(计为第0天)和口服基因工程化枯草芽孢杆菌孢子的胶囊后第14天血液中的抗体
SARS-CoV-2中和抗体的含量
志愿者 | 第0天 | 第14天 |
男性(58岁) | 0.08μg/ml | 0.082μg/ml |
男性(58岁) | 0.108μg/ml | 0.194μg/ml |
男性(55岁) | 0.073μg/ml | 0.090μg/ml |
从表1和表2中可以看出,口服表达SARS-CoV-2的N和S蛋白的基因工程化枯草芽孢杆菌能够产生抗体SARS-CoV-2中和抗体,从而对SARS-CoV-2进行治疗,表明表达N蛋白和S蛋白的枯草芽孢杆菌能够口服用作SARS-CoV-2感染的疫苗。
以上所述是本发明针对一种案例设计的实施方案,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下还可以作出若干改进,这些改进也应视为本发明的保护范围。
序列表
<110> 申请人名称 萝芊细胞因子有限公司
<120> 一种用于COVID-19的口服性疫苗及抗体加强剂
<130> 本所案号 GWGC210906DI-LQ
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1260
<212> DNA
<213> 人工序列(Artificial sequence)
<400> 1
atgtcagaca atggccctca aaaccagaga aacgctcccc gtataacttt tggaggaccg 60
tcggattcaa caggtagcaa tcagaatggc gagagatctg gcgcaaggag taaacagcgg 120
agaccccagg gattacccaa taatacagcc tcatggttta ctgccctaac tcagcatggc 180
aaagaagatc ttaagtttcc tcggggtcaa ggcgtaccca taaatacaaa ttcttccccg 240
gatgatcaaa tcggatacta tcgcagggcg actagacgca tcagaggcgg cgatggcaag 300
atgaaggatc tgagtcccag atggtatttt tattatttgg gaacaggacc cgaggcagga 360
ttaccgtatg gagcaaacaa ggatgggatt atttgggtgg ctacggaagg agcattaaat 420
actccgaagg atcacattgg tactcggaac ccggcaaaca atgctgctat tgtccttcaa 480
ttaccacaag gcacgacctt accgaaaggc ttttacgcgg aaggttcccg cggcggctct 540
caggcaagct cacgttcatc atccagatct cgtaatagca gccggaactc aacacccgga 600
agttcgagag ggacaagccc tgcgcgaatg gcaggaaacg gtggcgacgc cgcgctcgcc 660
ttgttgcttt tggatcggtt gaatcagctt gagtcaaaaa tgtctggaaa ggggcaacaa 720
caacaaggtc aaacagtgac gaaaaaatca gctgcggaag cgtcaaaaaa accccgtcaa 780
aaacgcacgg ctacaaaggc gtataacgta acacaagcat ttggaagaag ggggccggaa 840
caaacgcaag gtaattttgg agatcaagaa ctgattaggc agggcacaga ctataaacac 900
tggccgcaga tcgcacagtt tgcgcccagc gcgtcggcat ttttcggcat gtcgcgtatt 960
ggaatggagg tcacacccag cggcacatgg cttacgtata ccggcgcgat caagctcgac 1020
gataaagatc ctaactttaa agatcaggta atactgttga acaagcatat agacgcttac 1080
aaaacgtttc cccctacaga acctaaaaaa gataaaaaaa aaaaagcgga tgagacccaa 1140
gcgttacccc agagacagaa gaaacaacaa acagtgacac tgttaccagc cgcagatctg 1200
gatgatttta gcaaacagtt acaacagtct atgtcttccg ctgattcaac acaagcgtaa 1260
<210> 2
<211> 590
<212> DNA
<213> 人工序列(Artificial sequence)
<400> 2
aatatcacga atttgtgccc atttggcgaa gtattcaacg caacgagatt tgcctccgtt 60
tatgcgtgga accggaagag aatctcaaat tgtgtcgcgg attatagcgt cctgtataat 120
tcagcgtcat tctccacctt taagtgctac ggcgtgtcac caacgaaatt gaatgatctg 180
tgtttcacta atgtatatgc agatagcttt gtgatccgcg gcgacgaagt cagacaaatt 240
gcgccaggcc aaacgggaaa aatcgcagat tataattata aacttcctga tgacttcacg 300
ggatgtgtaa ttgcatggaa ctctaataac cttgattcga aagtcggagg aaattataac 360
tatctgtata gactgttccg caagagcaat ctcaagcctt tcgaacgcga tatctcgacg 420
gagatttatc aagccggcag caccccgtgt aacggtgttg aaggcttcaa ttgctatttc 480
ccgctgcaga gctatggctt tcaaccgacg aacggggttg gctaccagcc ctaccgcgtc 540
gtggttctgt ccttcgaatt actccatgcc ccggctacgg tttaatgaaa 590
<210> 3
<211> 1716
<212> DNA
<213> 人工序列(Artificial sequence)
<400> 3
tcacagaaaa agaacgggaa aagatgatgt aagcgtgaaa aattttttat cttatcactt 60
gaaattggaa gggagattct ttattataag aattgtggaa ttgtgagcgg ataacaattc 120
ccaattaaag gaggaaggat ccatgggcta ctataaaaaa tacaaagaag aatactatac 180
cgttaaaaag acatattaca agaagtatta tgagtacgat aaaaaagact atgattgtga 240
ttacgataaa aaatatgatg actatgataa aaaatattac gatcatgata aaaaagacta 300
tgattatgta gtagaatata aaaagcacaa aaaacattac gggggcgggg aggccgctgc 360
gaaaggtggc ggcatgtcag acaatggccc tcaaaaccag agaaacgctc cccgtataac 420
ttttggagga ccgtcggatt caacaggtag caatcagaat ggcgagagat ctggcgcaag 480
gagtaaacag cggagacccc agggattacc caataataca gcctcatggt ttactgccct 540
aactcagcat ggcaaagaag atcttaagtt tcctcggggt caaggcgtac ccataaatac 600
aaattcttcc ccggatgatc aaatcggata ctatcgcagg gcgactagac gcatcagagg 660
cggcgatggc aagatgaagg atctgagtcc cagatggtat ttttattatt tgggaacagg 720
acccgaggca ggattaccgt atggagcaaa caaggatggg attatttggg tggctacgga 780
aggagcatta aatactccga aggatcacat tggtactcgg aacccggcaa acaatgctgc 840
tattgtcctt caattaccac aaggcacgac cttaccgaaa ggcttttacg cggaaggttc 900
ccgcggcggc tctcaggcaa gctcacgttc atcatccaga tctcgtaata gcagccggaa 960
ctcaacaccc ggaagttcga gagggacaag ccctgcgcga atggcaggaa acggtggcga 1020
cgccgcgctc gccttgttgc ttttggatcg gttgaatcag cttgagtcaa aaatgtctgg 1080
aaaggggcaa caacaacaag gtcaaacagt gacgaaaaaa tcagctgcgg aagcgtcaaa 1140
aaaaccccgt caaaaacgca cggctacaaa ggcgtataac gtaacacaag catttggaag 1200
aagggggccg gaacaaacgc aaggtaattt tggagatcaa gaactgatta ggcagggcac 1260
agactataaa cactggccgc agatcgcaca gtttgcgccc agcgcgtcgg catttttcgg 1320
catgtcgcgt attggaatgg aggtcacacc cagcggcaca tggcttacgt ataccggcgc 1380
gatcaagctc gacgataaag atcctaactt taaagatcag gtaatactgt tgaacaagca 1440
tatagacgct tacaaaacgt ttccccctac agaacctaaa aaagataaaa aaaaaaaagc 1500
ggatgagacc caagcgttac cccagagaca gaagaaacaa caaacagtga cactgttacc 1560
agccgcagat ctggatgatt ttagcaaaca gttacaacag tctatgtctt ccgctgattc 1620
aacacaagcg taatgaaatc tagagtcgac gtccccgggg cagcccgcct aatgagcggg 1680
cttttttcac gtcacgcgtc catggagatc tttgtc 1716
<210> 4
<211> 1125
<212> DNA
<213> 人工序列(Artificial sequence)
<400> 4
ccgcggaagg gggggcggaa agatgatgta agcgtgaaaa attttttatc ttatcacttg 60
aaattggaag ggagatcttt attataagaa ttgtggaatt gtgagcggat aacaattccc 120
aattaaagga ggaaggatcc atgggctact ataaaaaata caaagaagaa tactataccg 180
ttaaaaagac atattacaag aagtattatg agtacgataa aaaagactat gattgtgatt 240
acgataaaaa atatgatgac tatgataaaa aatattacga tcatgataaa aaagactatg 300
attatgtagt agaatataaa aagcacaaaa aacattacgg gggcggggag gccgctgcga 360
aaggtggcgg caatatcacg aatttgtgcc catttggcga agtattcaac gcaacgagat 420
ttgcctccgt ttatgcgtgg aaccggaaga gaatctcaaa ttgtgtcgcg gattatagcg 480
tcctgtataa ttcagcgtca ttctccacct ttaagtgcta cggcgtgtca ccaacgaaat 540
tgaatgatct gtgtttcact aatgtatatg cagatagctt tgtgatccgc ggcgacgaag 600
tcagacaaat tgcgccaggc caaacgggaa aaatcgcaga ttataattat aaacttcctg 660
atgacttcac gggatgtgta attgcatgga actctaataa ccttgattcg aaagtcggag 720
gaaattataa ctatctgtat agactgttcc gcaagagcaa tctcaagcct ttcgaacgcg 780
atatctcgac ggagatttat caagccggca gcaccccgtg taacggtgtt gaaggcttca 840
attgctattt cccgctgcag agctatggct ttcaaccgac gaacggggtt ggctaccagc 900
cctaccgcgt cgtggttctg tccttcgaat tactccatgc cccggctacg gtttaatgaa 960
atctagagtc gacgtccccg gggcagcccg cctaatgagc gggctttttt cacgtcacgc 1020
gtccatggag atctttgtct gcaactgaaa agtttatacc ttacctggaa caaatggttg 1080
aaacatacga ggctaatatc ggcttattag gaatagtccc tgtac 1125
Claims (10)
1.一种枯草芽孢杆菌,其特征在于,所述的枯草芽孢杆菌表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域。
2.如权利要求1所述的枯草芽孢杆菌,其特征在于,枯草芽孢杆菌的菌株包括枯草芽孢杆菌WB800N菌株。
3.一种转化子,其特征在于,所述的转化子包括含有表达SARS-CoV-2的核衣壳蛋白和/或SARS-CoV-2的刺突蛋白的受体结合区域的基因的枯草芽孢杆菌。
4.如权利要求3所述的转化子,其特征在于,所述的基因掺入或导入到所述的枯草芽孢杆菌中。
5.一种组合物,其特征在于,所述的组合物包括如权利要求1所述的枯草芽孢杆菌和/或如权利要求3所述的转化子。
6.如权利要求5所述的组合物,其特征在于,所述的组合物为药物组合物或疫苗组合物。
7.如权利要求5所述的组合物,其特征在于,所述的组合物的剂型为口服制剂。
8.一种如权利要求1所述的枯草芽孢杆菌和/或如权利要求3所述的转化子的用途,其特征在于,用于制备组合物,所述的组合物用于预防和/或治疗SARS-CoV-2病毒感染或COVID-19;和/或用作SARS-CoV-2抗体的加强剂。
9.一种制备抗SARS-CoV-2的核衣壳蛋白和/或抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体的方法,其特征在于,所述的方法包括步骤:
将如权利要求1所述的枯草芽孢杆菌和/或如权利要求3所述的转化子口服给药对象,从血液中分离得到抗SARS-CoV-2的核衣壳蛋白的抗体和/或抗SARS-CoV-2病毒的刺突蛋白的受体结合区域的抗体,预防和/或治疗SARS-CoV-2病毒感染或COVID-19。
10.一种预防和/或治疗SARS-CoV-2病毒感染或COVID-19的方法,其特征在于,口服给予所述的对象如权利要求1所述的枯草芽孢杆菌和/或如权利要求3所述的转化子,而预防和/或治疗SARS-CoV-2病毒感染或COVID-19。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111143384.9A CN113755421B (zh) | 2021-09-28 | 2021-09-28 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111143384.9A CN113755421B (zh) | 2021-09-28 | 2021-09-28 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113755421A true CN113755421A (zh) | 2021-12-07 |
CN113755421B CN113755421B (zh) | 2024-04-12 |
Family
ID=78797944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111143384.9A Active CN113755421B (zh) | 2021-09-28 | 2021-09-28 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113755421B (zh) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060140971A1 (en) * | 2003-06-04 | 2006-06-29 | Moon-Hee Sung | Cell surface expression vector of sars virus antigen and microorganisms transformed thereby |
CN111607003A (zh) * | 2020-05-21 | 2020-09-01 | 泰州市百英生物科技有限公司 | 一种SARS-CoV-2 N/S1(RBD)重组蛋白及制备方法和应用 |
CN111732638A (zh) * | 2020-07-02 | 2020-10-02 | 重庆博唯佰泰生物制药有限公司 | 一种针对SARS-CoV-2的疫苗 |
CN112552380A (zh) * | 2020-12-10 | 2021-03-26 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
US10973908B1 (en) * | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN112979829A (zh) * | 2021-04-29 | 2021-06-18 | 诺未科技(北京)有限公司 | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 |
CN113101377A (zh) * | 2021-04-09 | 2021-07-13 | 翁炳焕 | 一种以重组益生菌为载体的冠状病毒口服疫苗 |
CN113173977A (zh) * | 2021-05-12 | 2021-07-27 | 江苏坤力生物制药有限责任公司 | 一种双功能抗原、其制备方法及应用 |
CN113186223A (zh) * | 2021-06-17 | 2021-07-30 | 浙江格源致臻生物医药科技有限公司 | 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗 |
GB2592769A (en) * | 2020-03-01 | 2021-09-08 | Valneva Austria Gmbh | CpG-adjuvanted SARS-CoV-2 virus vaccine |
CN113388633A (zh) * | 2020-03-11 | 2021-09-14 | 梦芊科技知识产权有限公司 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
WO2021179418A1 (en) * | 2020-03-09 | 2021-09-16 | Tsinghua University | Detection of immune response to sars-cov-2 |
WO2021206587A1 (en) * | 2020-04-10 | 2021-10-14 | Genetic Diagnostics And Therapy 21 Ltd | Sars-cov-2 dna vaccine based on gene therapy dna vector gdtt1.8nas12 |
WO2022049381A1 (en) * | 2020-09-03 | 2022-03-10 | Sporegen Limited | Treatment and prevention of viral infections |
WO2022096899A1 (en) * | 2020-11-09 | 2022-05-12 | Autolus Limited | Viral spike proteins and fusion thereof |
US20230227537A1 (en) * | 2020-02-06 | 2023-07-20 | Vib Vzw | Corona virus binders |
US20230257425A1 (en) * | 2020-04-29 | 2023-08-17 | Sk Bioscience Co., Ltd. | Vaccine composition for preventing or treating infection of sars-cov-2 |
-
2021
- 2021-09-28 CN CN202111143384.9A patent/CN113755421B/zh active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060140971A1 (en) * | 2003-06-04 | 2006-06-29 | Moon-Hee Sung | Cell surface expression vector of sars virus antigen and microorganisms transformed thereby |
US20230227537A1 (en) * | 2020-02-06 | 2023-07-20 | Vib Vzw | Corona virus binders |
GB2592769A (en) * | 2020-03-01 | 2021-09-08 | Valneva Austria Gmbh | CpG-adjuvanted SARS-CoV-2 virus vaccine |
WO2021179418A1 (en) * | 2020-03-09 | 2021-09-16 | Tsinghua University | Detection of immune response to sars-cov-2 |
CN113388633A (zh) * | 2020-03-11 | 2021-09-14 | 梦芊科技知识产权有限公司 | 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子 |
WO2021206587A1 (en) * | 2020-04-10 | 2021-10-14 | Genetic Diagnostics And Therapy 21 Ltd | Sars-cov-2 dna vaccine based on gene therapy dna vector gdtt1.8nas12 |
US20230257425A1 (en) * | 2020-04-29 | 2023-08-17 | Sk Bioscience Co., Ltd. | Vaccine composition for preventing or treating infection of sars-cov-2 |
US10973908B1 (en) * | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN111607003A (zh) * | 2020-05-21 | 2020-09-01 | 泰州市百英生物科技有限公司 | 一种SARS-CoV-2 N/S1(RBD)重组蛋白及制备方法和应用 |
CN111732638A (zh) * | 2020-07-02 | 2020-10-02 | 重庆博唯佰泰生物制药有限公司 | 一种针对SARS-CoV-2的疫苗 |
WO2022049381A1 (en) * | 2020-09-03 | 2022-03-10 | Sporegen Limited | Treatment and prevention of viral infections |
WO2022096899A1 (en) * | 2020-11-09 | 2022-05-12 | Autolus Limited | Viral spike proteins and fusion thereof |
CN112552380A (zh) * | 2020-12-10 | 2021-03-26 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
CN113101377A (zh) * | 2021-04-09 | 2021-07-13 | 翁炳焕 | 一种以重组益生菌为载体的冠状病毒口服疫苗 |
CN112979829A (zh) * | 2021-04-29 | 2021-06-18 | 诺未科技(北京)有限公司 | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 |
CN113173977A (zh) * | 2021-05-12 | 2021-07-27 | 江苏坤力生物制药有限责任公司 | 一种双功能抗原、其制备方法及应用 |
CN113186223A (zh) * | 2021-06-17 | 2021-07-30 | 浙江格源致臻生物医药科技有限公司 | 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗 |
Non-Patent Citations (16)
Title |
---|
AHMED S 等: "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies", 《VIRUSES》, vol. 12, no. 3, pages 2, XP055716518, DOI: 10.3390/v12030254 * |
BERTOGLIO F 等: "Chain E, Spike protein S1", 《GENBANK DATABASE》, pages 7 * |
HINC K 等: "New stable anchor protein and peptide linker suitable for successful spore surface display in B. subtilis", 《MICROB CELL FACT》, vol. 12, 28 February 2013 (2013-02-28), pages 1 - 8 * |
JIA Q 等: "Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters", 《NPJ VACCINES》, vol. 6, no. 1, 30 March 2021 (2021-03-30), pages 1 - 13 * |
LV P 等: "Application of Bacillus subtilis as a live vaccine vector: A review", 《J VET MED SCI》, vol. 82, no. 22, pages 1693 - 1699 * |
SUNG J 等: "Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate", 《VACCINES (BASEL)》, vol. 10, no. 11, pages 1 - 10 * |
VETRÁKOVÁ A 等: "Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein", 《 COMPUT STRUCT BIOTECHNOL J》, vol. 2019, no. 21, pages 1550 - 1556 * |
VILLENA J 等: "Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines", 《MICROORGANISMS》, vol. 9, no. 4, 26 March 2021 (2021-03-26), pages 1 - 26, XP055872044, DOI: 10.3390/microorganisms9040683 * |
WANG M 等: "A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》, 30 May 2020 (2020-05-30), pages 1 - 14 * |
WU F 等: "nucleocapsid phosphoprotein [Severe acute respiratory syndrome coronavirus 2]", 《GENBANK DATEBASE》, vol. 2007, pages 009724397 * |
YANG J 等: "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", 《NATURE》, vol. 586, no. 7830, pages 572, XP037277111, DOI: 10.1038/s41586-020-2599-8 * |
于永利: "严重急性呼吸综合征冠状病毒2疫苗", 《微生物学免疫学进展》, vol. 48, no. 4, pages 1 - 7 * |
张婷 等: "新型冠状病毒S蛋白RBD的糖基化及其长度对蛋白疫苗免疫原性的影响", 《基础医学与临床》, vol. 40, no. 12, pages 1645 - 1650 * |
李建娜 等: "SARS病毒S蛋白的原核表达与DNA疫苗的构建", 《第一军医大学学报》, no. 1, pages 33 - 36 * |
秦照玲 等: "严重急性呼吸综合征冠状病毒2核衣壳蛋白原核表达、纯化及其抗血清制备", 《第二军医大学学报》, vol. 41, no. 5, pages 482 * |
苗雨 等: "一种展示SARS冠状病毒受体结合区的重组枯草杆菌芽孢的制备及免疫原性分析", 《生物技术通讯》, vol. 24, no. 3, pages 343 * |
Also Published As
Publication number | Publication date |
---|---|
CN113755421B (zh) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018124393A1 (ko) | 브루셀라 균 주요 공통 항원을 발현하는 lps의 o-항원 결실 비병원성 살모넬라 균주를 포함하는 브루셀라증 예방 또는 치료용 백신 조성물 | |
Kato et al. | Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses | |
US7128916B2 (en) | Bacteriophage-mediated immunisation | |
US11318174B2 (en) | Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses | |
CN105753989A (zh) | 人工多抗原融合蛋白及其制备和应用 | |
AU2016302436B2 (en) | Enhanced immune response in porcine species | |
EP1071452A1 (en) | Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof | |
CN113755421A (zh) | 一种用于covid-19的口服性疫苗及抗体加强剂 | |
US20090162324A1 (en) | Use of Whole Cell Actinomycetales Bacteria to Treat Stress-Induced Pulmonary Haemorrhage | |
EP2508200B1 (en) | Carbonic anhydrase i serving as novel antigen to be used for treatment of autoimmune diseases | |
EP2724726A1 (en) | Use of intranasally administered Pidotimod to enhance antigen-specific humoral and cell-mediated immune response | |
RU2489165C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА К Мусоbacterium avium ПОДВИДА Paratuberculosis | |
US11911459B2 (en) | Nant COVID vaccine cross reactivity | |
US20090074815A1 (en) | Immunomodulator Compounds as Vaccine Enhancers | |
Chaudhary et al. | A New Vaccine Strategy of Dendritic Cell Presented Kinetoplastid Membrane (KMP-11) as Immunogen for Control against Experimental Visceral Leishmaniasis | |
US20100284963A1 (en) | Growth regulatable recombinant bcg immunogenic compositions | |
US8383132B2 (en) | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use | |
RU2778094C2 (ru) | Композиции для применения в качестве профилактического средства для пациентов с риском туберкулезной инфекции или в качестве вторичных средств для лечения пациентов с туберкулезной инфекцией | |
CN108239660B (zh) | 一种重组结核病疫苗,其制备方法及应用 | |
Won et al. | A novel approach for construction of an inactivated typhoid vaccine candidate that effectively augments both humoral and cellular immune responses | |
Gao et al. | Saccharomyces cerevisiae oral immunization in mice using multi-antigen of the African swine fever virus elicits a robust immune response | |
CN113930438A (zh) | 一种重组的耻垢分枝杆菌、疫苗及其应用 | |
US20180243390A1 (en) | Inflammasome activators and methods of use to treat tumors | |
CN118086212A (zh) | 新冠病毒表位多肽致敏的树突状细胞及其应用 | |
Boraschi | Vaccines of the Future: The Role of Inflammation and Adjuvanticity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Room g, 12 / F, city industrial building, 71-77 Yau Ma Hom Road, Kwai Chung, Hong Kong, China Applicant after: Mengqian Cytokines Co.,Ltd. Address before: Room g, 12 / F, city industrial building, 71-77 Yau Ma Hom Road, Kwai Chung, Hong Kong, China Applicant before: Luoqian cytokine Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |